Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Opinion Volume 6 Issue 5

Why is there a Fear of Coronavirus?

Igor Klepikov*

MD, Professor, Retired, Renton, WA, USA

*Corresponding Author: Igor Klepikov, MD, Professor, Retired, Renton, WA, USA.

Received: April 06, 2022; Published: April 25, 2022

It has been more than two years since the SARS-CoV-2 pandemic swept the world. During this time, not only vaccines were created to protect against this infection, but also vaccination of the population of many countries was started, followed by the preservation of the effect by the introduction of booster doses. Preventive measures have been expanded through the introduction of unprecedented quarantine measures. After a long implementation of such unusual preventive measures, it would seem that it is already possible to get rid of the feeling of fear and uncertainty before the trouble that has arisen. However, the surrounding reality shows that there has not been a complete reduction in tension due to the pandemic, and the fear of the danger of a disease with an uncertain outcome has not decreased even among passionate followers of protective measures.


  1. “Coronavirus”.
  2. Rawson TM., et al. “Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing”. Clinical Infectious Disease (2020): ciaa 530.
  3. BO’Kelly., et al. “Antibiotic prescribing patterns in patients hospitalized with COVID-19: lessons from the first wave”. JAC - Antimicrobial Resistance2 (2021): dlab085.
  4. Puzniak L., et al. “A multicenter analysis of the clinical microbiology and antimicrobial usage in hospitalized patients in the US with or without COVID-19”. BMC Infectious Disease 21 (2021): 227.
  5. Kim D., et al. “Rates of co-infection between SARS-CoV-2 and other respiratory pathogens”. JAMA 323 (2020): 2085-2086.
  6. B Beović., et al. “Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey”. Journal of Antimicrobial Chemotherapy (2020): dkaa326.
  7. Ocampo-Torres Moisés., et al. “Characterization of Mortality by Covid-19 in a Health System in Central Mexico”. EC Pulmonology and Respiratory Medicine12 (2020): 20-22.
  8. Alejandro David Bendala Estrada., et al. “Inadequate Use of Antibiotics in the Covid-19 Era: Effectiveness of Antibiotic Therapy”. (2021).
  9. BD Huttner., et al. “COVID-19: don't neglect antimicrobial stewardship principles!” Clinical Microbiology and Infection 7 (2020): P808-810.
  10. C Heneghan., et al. “Differentiating viral from bacterial pneumonia. April 8, 2020. The Centre for Evidence-Based Medicine. Evidence Service to support the COVID-19 response”. University of Oxford (2020).
  11. Lipman M., et al. “SARS-CoV-2 pandemic: clinical picture of COVID-19 and implications for research”. Thorax 75 (2020): 614-616.
  12. “Revised global burden of disease 2002 estimates” (2004).
  13. Rudan I., et al. “Epidemiology and etiology of childhood pneumonia”. Bulletin of the World Health Organization 86 (2008): 408-416.
  14. Ruuskanen O., et al. “Viral pneumonia". Lancet 9773 (2011): 1264-1275.
  15. JP Metlay., et al. “Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America”. American Journal of Respiratory and Critical Care Medicine7 (2019): e45-e67.
  16. Paula Peyrani., et al. “The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance”. Expert Review of Respiratory Medicine2 (2019): 139-152.
  17. Cilloniz C., et al. “Management of pneumonia in critically ill patients”. BMJ 375 (2021): e065871.
  18. Ing AJ., et al. “COVID-19: in the footsteps of Ernest Shackleton”. Thorax 75 (2020): 693-694.
  19. Z Wu., et al. “Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention”. JAMA 13 (2020): 1239-1242.
  20. Gandhi RT., et al. “Mild or moderate Covid-19”. The New England Journal of Medicine NEJMcp2009249, (2020).
  21. Merad M and Martin JC. “Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages”. Nature Reviews Immunology 20 (2020): 355-362.
  22. Ra SH., et al. “Upper respiratory viral load in asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2 infection”. Thorax 76 (2021): 61-63.
  23. Zhou B., et al. “COVID‐19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations”. Journal of Medical Virology (2021): 1-11.
  24. “Meme”.
  25. Easley D. “Networks, Crowds and Markets: Reasoning about a Highly Connected World”. Cambridge University Press. Chapter 16 (2010).
  26. Igor Klepikov. “5 modern myths about acute pneumonia”. International Academic Journal of Medical and Clinical Practice 3 (2021): 6-20.
  27. Klepikov I. “Acute Pneumonia and the Hidden Effect of Antibiotics”. Journal of Pulmonary Diseases and Respiratory Medicine 2 (2020): 108.
  28. Igor Klepikov. “Principles of emergency care for acute pulmonary inflammation”. Academic Journal of Nursing and Health Education3 (2021): 1-9.


Citation: Igor Klepikov. “Why is there a Fear of Coronavirus?”.Acta Scientific Medical Sciences 6.5 (2022): 168-172.


Copyright: © 2022 Igor Klepikov. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

Contact US